We previously reported feasibility and efficacy of a monocentric pilot study of intensive sequential chemotherapy (ISC) in poor-risk aggressive non-Hodgkin's lymphoma (NHL) in patients Ͻ60 years. To validate these results on a large cohort of patients, we designed a new and oligocentric study. After a COP (cyclophosphamide (Cy), vincristine (Vcr), prednisone (Pred) debulking, patients received four courses of high-dose CHOP (Cy, doxorubicin (Doxo), Ver, Pred), with the addition of etoposide and cisplatin during the two last courses. G-CSF was delivered after each cycle, and peripheral blood stem cells (PBSC) were used to support the two last cycles. Total duration of chemotherapy was 13 weeks, with a planned dose-intensity (DI) of 1420 mg/m 2 /week and 23 mg/m 2 /week for Cy and Doxo, respectively. Radiotherapy (involved fields) was then delivered for patients with node size у5 cm at diagnosis. Forty-two patients were enrolled in this study; 36 completed the treatment and received 75% or more of the planned DI for both Cy and Doxo. Median duration of grade 4 neutropenia was 14 days (range, 2 to 28) for the regimen as a whole, and median duration of rehospitalization for febrile neutropenia was 18 days (range, 4 to 41). Overall response rate was 83%, with 29 patients (69%) in complete response (CR). Six patients failed to respond and one died of toxicity. With a median follow-up of 22.5 months (range, 10 to 42), the 3-year event-free survival (EFS) is 55% (95% CI, 39-71), while disease-free survival (DFS) is 79% (95% CI, 63-95). Ambulatory ISC is accessible and feasible in an oligocentric study. PBSC allow repeated delivery of high-dose chemotherapy cycles, and result in encouraging CR, EFS, and DFS rates for poor-risk aggressive NHL's patients.
Introduction
During the past two decades, combination-chemotherapy regimens using doxorubicin, cyclophosphamide, and vincristine have shown that large-cell lymphoma (LCL) is a potentially curable malignancy. 1 CHOP regimen was extensively used in LCL patients and may cure approximately 30% of patients. 2 Several studies using new combination-chemotherapy regimens modeled on CHOP demonstrated improved results. [3] [4] [5] However, when compared in a prospective randomized phase III trial, there was no significant difference between these regimens (CHOP, m-BACOD, MACOP-B, Pro-MACE-CytaBOM) in terms of complete response (CR) rate and survival at 3 years.
national Prognostic Index (Aa-IPI) established that patients in high-intermediate (HI)-risk (score 2) or high (H)-risk (score 3) groups had a poor outcome when treated with conventional chemotherapy. 7 Many studies investigated the role of highdose therapy (HDT) followed by autologous bone marrow/stem cell transplantation (ABMT/ASCT). Results were highly promising, showing that such a strategy could improve CR and survival rates. [8] [9] [10] [11] [12] The Groupe d'Etude des Lymphomes de l'Adulte (GELA) reported the results of the LNH-87 protocol comparing sequential conventional-dose chemotherapy to high-dose therapy supported by ABMT. For patients with two or three factors of the Aa-IPI, relapse-free survival was significantly improved for transplanted patients. 10 More recently, Santini et al reported the results of a multicenter randomized study comparing conventional therapy and conventional therapy plus HDT with ABMT. Disease-free survival and progression-free survival were improved for HI-risk and H-risk patients who received HDT and ABMT. 13 Other strategies with HDT as front-line treatment were also tested in this group of patients. 14, 15 The rationale of these treatments was to augment the dose-intensity (DI) of the principal drugs used in the field of lymphomas. We previously reported feasibility and efficacy of intensive sequential chemotherapy (ISC) with repeated peripheral blood stem cell (PBSC) support as front-line therapy in 20 adult patients р60 years of age with agressive histology and poor-risk factors. This was a monocentric pilot study, and our preliminary results were encouraging, with 2-year overall survival (OS) and diseasefree survival (DFS) at 73% and 86%. 16 We then initiated a second pilot trial of ISC (ISC 95), supported by growth factors and PBSC. ISC 95 was designed as an oligocentric trial, to make the use of ISC more accessible for a large cohort of patients. This regimen included four highdose CHOP, with the addition of etoposide and cisplatin during the two last cycles. These drugs were chosen according to our experience with the ISC 92 regimen. The rationale was to reinforce the two last cycles with non-cross-resistant active drugs, considering that during these cycles additional hematological toxicity will be limited by the scheduled stem cell reinfusion. Total duration of chemotherapy was 13 weeks for ISC 95, leading to a higher relative DI for Cy, and an equivalent DI for Doxo than the ISC 92 regimen. We report here the results of 42 patients with HI-risk and H-risk aggressive NHL from three institutions.
Patients and methods

Patients
From March 1995 to March 1998, 42 adult patients from three institutions were eligible for the ISC 95 regimen. Inclusion cri-teria were: age between 15 and 60 years, an aggressive histology such as described in the REAL classification, 17 and at least two adverse prognostic factors from the Aa-IPI. Patients had to be free of any previous treatment. All underwent physical examination, whole body CT scan, bone marrow biopsy, and lumbar puncture. Other examinations such as gastrointestinal or pulmonary endoscopies, bone scintigraphy, or liver biopsy were performed according to the site of disease. Patients were informed of the nature of the study and informed consent was required in accordance with institutional guidelines. Figure 1 from the study if conditions of delivery of chemotherapy could not be respected.
Treatment (
Colony-stimulating factors:
Except for COP, filgrastim (G-CSF) at 300 g/day was administered subcutaneously and started at d 6 for a minimum of 7 days, or until apheresis completion or neutrophil recovery (at least 2 consecutive days with у0.5 × 10 9 /l).
Peripheral blood stem cells (PBSC):
PBSC were collected after C1. If the required number of CD34 + cells was not reached, a second series of aphereses was performed after C2. A minimum of 6 × 10 6 CD34 + cells/kg was required to continue the chemotherapy regimen. In fact, to ensure the overall safety of the procedure (outpatient setting), this value was chosen as a target. Patients who did not meet this criteria were withdrawn from the study. Aphereses were performed as previously described. 16 PBSCs were then infused at d 4 of C3 and C4, with a minimum of 2 × 10 6 CD34 + cells/kg per infusion.
Radiotherapy (RT):
RT was delivered each time size node at diagnosis was у5 cm. Involved fields were irradiated with a total dose of 45 Gy, planned within 2 months of end of chemotherapy. Patients with extranodal localization of the disease also received radiotherapy with regard to the site of the initial tumor.
Concomitant medications:
Oral prophylactic antibiotics were given from d 6 until neutrophil recovery and consisted of penicillin G (1 × 10 6 U twice daily) and ciprofloxacin (750 mg twice daily). When patients were hospitalized for febrile neutropenia, such treatment was stopped and i.v. antibiotherapy was started. Red blood cell transfusion was delivered each time hemoglobin level dropped below 80 g/l. Our criteria of platelet transfusion were a platelet count under 10 × 10 9 /l, or any symptoms of bleeding with a platelet count under 952 50 × 10 9 /l. Patients were checked three times a week at our day care hospital where physical examination and laboratory tests were performed.
Assessment of dose intensity
Dose intensity in milligrams per m 2 per week was assessed for Cy and Doxo using the Hryniuck formula. 18 Duration of chemotherapy was calculated from day 1 of COP to day 21 of the last cycle of chemotherapy (C4). For patients who did not receive the total course, the planned duration of therapy (13 weeks) was used.
Response criteria
Response was evaluated 4 to 6 weeks after the last cycle of chemotherapy. For patients who underwent radiotherapy, a new staging was performed 1 month after completion of treatment. CR was defined as the complete disappearance of all measurable and evaluable disease. In our study, patients with a radiologic residual mass less than 2 cm were reconsidered as CR if no progression was observed within 3 months. Partial response (PR) was defined as diminution of у50% of all the initial masses. Failures in our study included all other situations.
Statistical analysis
Student's t-test was used to compare neutropenia and thrombopenia duration between the first (C1, C2) and the last cycles (C3, C4).
2 test was used to compare transfusion frequency. Analysis of variance was performed to compare the number of blood products transfused during the first and last cycles of chemotherapy. OS was calculated from the date of diagnosis, death being scored as an event with censoring of other patients at the time of last follow-up. Event-free survival (EFS) was calculated from the date of diagnosis, relapse, or progression, or death being scored as an event, with censoring of other patients at the time of last follow-up. DFS was calculated from the date of diagnosis, relapse being scored as an event, with censoring of other patients at the time of last follow-up. For survival curves, we used Kaplan and Meier estimates. Curves were compared by the log-rank test. Survival rates are presented with their 95% confidence intervals (95% CI).
Results
Patient characteristics
Patient characteristics are listed in Table 1 . There were 42 patients with a median age of 40 years (range, 19 to 60). Thirty-seven patients (88%) had an LCL. According to the Aa-IPI, 19 patients were in the HI-risk group, and 23 patients were in the H-risk group. Bone marrow (BM) involvement was especially prominent in our series, with 15 patients BM + (35%). The other extranodal localizations observed were: liver in six patients, bone in five, gastrointestinal tract in four, lung in four, and skin in four. DLCL, diffuse large cell lymphoma; ALCL, anaplastic large cell lymphoma (B cell = 1, T cell = 1, and null = 1); PTCL, pleimorphic T cell lymphoma.
Delivery of chemotherapy and dose intensity
Thirty-six patients (85%) completed the total course of chemotherapy, and received 75% or more of the planned DI for Doxo and Cy. Reasons for discontinuation of chemotherapy were: three patients with disease progression, one with grade 2 renal toxicity, one with hematological toxicity, and one with low CD34 + cell count. The median chemotherapy duration for the whole population was 13 weeks (range, 13 to 20). Sixteen patients (44%) received the regimen on time within 13 
G-CSF treatment and PBSC collection
The median duration of G-CSF delivery was 9 days (range, 4 to 16) after C1, 7 days (range, 6 to 10) after C2, 10 days (range, 3 to 15) after C3, and 8 days (range, 6 to 13) after C4. Collection of PBSC was performed for 40 patients (95%). Two patients were not collected due to disease progression after C1. A total of 74 aphereses were performed, 64 (86%) after one course of chemotherapy. The median number of aphereses per patient was two (range, 1 to 6), and median CD34 + cells collected was 9 × 10 6 /kg (range, 3.4 to 54). Thirty-six patients (90%) had у6 × 10 6 CD34 + cells/kg in the aphereses product.
Hematological toxicity (Table 2) Neutropenia:
Grade 4 neutropenia occurred in 90% of patients after C1, 67% after C2, 95% after C3, and 97% after C4. The median duration of grade 4 neutropenia for the whole procedure was 14 days (range, 2 to 28), with a statistically significant difference between stem cell supported or unsupported cycles (P = 0.01). Rehospitalization for febrile neutropenia occurred in 69%, 40%, 71%, and 83% of patients after cycles 1, 2, 3, and 4, respectively, and its median duration was 18 days (range, 4 to 41) for the whole regimen.
Thrombopenia:
Grade 4 thrombopenia occured more frequently after C3 (66%) and C4 (61%), than after cycles 1 and 2 (24% and 5%, respectively). Its median duration was significantly increased during the two last cycles (P Ͻ 0.0001).
Transfusions:
Both red blood cell (RBC) and platelet transfusions were required in this regimen, with a significant increase of transfusion frequency and number of transfused units during the two last cycles. Sixty-eight percent of patients required RBC transfusions during cycles 3 and 4, while 37% were transfused during cycles 1 and 2 (P Ͻ 0.0001). The median number of RBC transfusions was 2.5 and 1, respectively (P = 0.04). More patients required platelet transfusion during cycles 3 and 4 than during cycles 1 and 2 (55% vs 15%, P Ͻ 0.0001), while the number of platelet units used was not increased (1.5 vs 0.5, P = 0.08).
Extrahematological toxicity
The main extrahematological toxicities observed consisted of mucositis and documented infections. Frequency of these adverse events was not significantly increased with the repetition of cycles, although more grade у2 mucositis were observed after cycles 3 and 4 (37% and 50%) than after cycles 1 and 2 (19% and 10%, P = 0.20). There was no statistically significant difference in incidence of documented infections between the four courses of chemotherapy (19%, 10%, 13%, and 19% after cycles 1, 2, 3, and 4 respectively; P = 0.90). Five patients developed renal toxicity (grade 1: three patients; grade 2: two patients). All recovered normal renal function after symptomatic treatment (hydratation and diuretics). One patient died at day 26 after cycle 4 from acute respiratory distress syndrome, after developing a febrile interstitial pneumopathy and despite full neutrophil recovery.
Response and survival
An objective response (OR) was achieved in 35 patients (83%), with 29 patients (69%) in CR and six patients (14%) in PR. Six patients failed to respond, and one patient died of toxicity and was not evaluated for response. For patients who completed the four cycles of the chemotherapy regimen (n = 36), the CR rate was 80% (Table 3) .
With a median follow-up of 22.5 months (range, 10 to 42), 26 patients are alive, 23 in first CR, and three in second CR. OS and EFS at 3 years are at 58% (95% CI, 41-74) and 55% (95% CI, 39-71) respectively (Figure 2) . DFS for responder patients is at 79% (95% CI, 63-95) at 3 years ( Figure 3 ). Twelve relapses (33%) occurred in a median time of 8 months (range, 5 to 19). Of the 42 eligible patients, 16 died. Cause of death was NHL in 13 patients, infection in one, and toxic death in one. One patient died 10 months after completion of treatment from a road accident, while in CR.
Impact of radiotherapy as consolidation treatment was evaluated in patients who achieved CR after completion of chemotherapy (n = 29). Sixteen patients were eligible for additional radiotherapy because of a tumor size у5 cm at diagnosis. Irradiation of initial involved fields occurred in a median time of 8 weeks (range, 4 to 15) following the last cycle of chemotherapy. The median dose delivered was 40 Gy (range, 32 to 45). The 3-year OS of this group of patients Table 3 Response to treatment a Evaluable patients means patients who received total chemotherapeutic regimen. Of the 42 patients who fulfilled inclusion criteria, six patients did not complete total procedure: two stopped before C2: progression = 2; two stopped before C3: progression = 1; low CD34 count = 1; two stopped before C4: toxicity = 2 (hematological: 1, renal:1).
Figure 2
Overall survival (OS) and event-free survival for all eligible patients (n = 42).
Figure 3
Disease-free survival for CR patients (n = 29).
was 84%. Thirteen patients in CR were not eligible for additional radiotherapy, and their 3-year OS was 69% (P = 0.10).
Comparison of HI-risk patients (n = 19) and H-risk patients (n = 23) showed no statistically significant difference in overall survival (P = 0.22).
Discussion
HDT with ASCT used as front-line therapy in poor-risk NHL patients, particularly for those who achieved remission, has been extensively studied. 19 The development of both growth factors and PBSC support has allowed experimentation with new therapeutic strategies. One alternative approach is to intensify standard first-line regimens. The first study of highdose CHOP with G-CSF support as initial treatment in poorrisk NHL's patients was reported by Shipp et al. This was a dose-finding study of Doxo and Cy, and at the maximum tolerated dose the CR rate was 86%, with 79% of the complete responders remaining progression-free with a 20 month median follow-up. 14 In their study, Gianni et al 15 reported 98 patients with aggressive DLCL who received either MACOP-B, or high-dose sequential therapy followed by myeloablative treatment and bone marrow transplantation. Patients who received high-dose sequential therapy had significantly higher CR rates, freedom from disease progression, and event-free survival than patients who received conventional chemotherapy. Otherwise, a biweekly THP-COPBLM (pirarubicin, cy, vcr, pred, bleomycin, and procarbazine) regimen with G-CSF support was recently reported in 25 poor-risk NHL patients. CR was achieved in 21 patients and the 3-year eventfree survival was 58%. 20 In the monocentric ISC 92 regimen we reported, both G-CSF and PBSC were used to support chemotherapy. Treatment delivery was optimal, with 65% of patients achieving CR, and an actual 5-year DFS at 71%. 16 Unlike our previous study, the ISC 95 regimen was designed as an oligocentric trial in order to validate feasibility of such a procedure in a large cohort of patients. The characteristics of our population show the very poor prognosis of patients, 55% of them in the high-risk group, and 35% with bone marrow involvement at diagnosis. The ISC 95 regimen was feasible with 85% of patients completing the treatment. Only three patients had treatment stopped because of toxicity. Chemotherapy delivery was also optimal, with a relative dose intensity at 90% and 91% for Doxo and Cy, respectively. Hematological and extrahematological toxicities were comparable with those reported in ISC 92, except for increased frequency of rehospitalization for febrile neutropenia in the ISC 95 regimen. However, the median duration of rehospitalization remained short, less than 7 days per cycle. The procedure-related mortality was low in this group of poor-risk patients (2.5%). Despite the oligocentric design of the ISC 95 trial, response to treatment (CR, DFS, EFS) remained encouraging and comparable to that observed in the ISC 92 regimen. These results may contrast with those recently reported by Shipp et al 21 which suggest that high-dose induction therapy may be most effectively administered in specialized institutions. However, in this report Shipp considers any center which treated at least three patients as a high accrual institution. In the ISC 95 study, none of the three participating centers included less than three patients.
These two consecutive pilot studies of ISC conducted with G-CSF and PBSC support prove the feasibility of such a procedure in poor-risk NHL patients with added data reproducibility. Our results compare favorably with those achieved with ABMT/ASCT in first remission. The choice between these two strategies (ISC vs HDT with ASCT) will depend on the experience of physicians involved in patient care, however a randomized study comparing the two approaches should now be designed.
Despite these encouraging results of HDT in poor-risk NHL patients, approximately 30% remain refractory or relapse earlier. It is probably necessary to investigate more appropriate prognostic factors, and subsequently new therapeutic strategies. The way to improve upon the International Index is currently being investigated. A recent review highlighted the biological heterogeneity of aggressive NHL. 22 Many biological variables have been evaluated, with some shown to be relevant as prognostic factors. The recent report of Gisselbrecht et al 23 showed the poor prognosis value of T cell phenotype in aggressive NHL patients. In our report, the number of patients with PTCL was low so did not allow statistical analysis. Otherwise, contamination of PBSC by tumor cells could explain the relapse. 24 However, the relapse rate we observed does not vary from those reported in the literature for this group of patients who received HDT with ASCT after reaching CR. Our data do not show a deleterious effect of stem cell reinfusion, but the new purging methods need to be investigated.
On the other hand, treatment of these patients must be improved. The majority of studies of the literature investigated the role of chemotherapy alone. In our study, adjuvant radiotherapy was applied to sites of previous bulky disease in patients who were in CR after chemotherapy. Although survival was not significantly different between the two groups of patients, a trend towards longer survival was found for those who received radiotherapy. In fact, relapse occurs more frequently on sites of previous disease, and early adjuvant radiotherapy may improve patient survival. 25 However, indications of radiotherapy as consolidation treatment remain variable. Better selection of patients is required in order to define the role of adjuvant radiotherapy. The recent report of Miller et al 26 demonstrates that additional radiotherapy to three cycles of CHOP is superior to eight cycles of CHOP alone for the treatment of localized intermediate and highgrade NHL. Another approach in the treatment of LCL patients is the use of adjuvant immunotherapy to increase host immune response. Studies testing efficacy of Interferon-alpha after autologous transplantation are still ongoing. There are also interesting data of Interleukin-2 in refractory or relapsed patients. 27 Recent data of the anti-CD20 monoclonal antibody are more encouraging. Anti-CD20 is well tolerated and has clinical activity in patients with relapsed or refractory aggressive B cell lymphoma. 28, 29 Perhaps the use of anti-CD20 as consolidation treatment after HDT will contribute to reducing relapse rate in poor-risk LCL patients.
Finally, repeated very high-dose chemotherapy cycles with growth factors and peripheral blood stem cell support are feasible in oligocentric studies. Patients with high-intermediate and high-risk aggressive NHL seem to benefit from such a strategy, however the follow-up remains short. Additional use of both radiotherapy and immunotherapy could probably contribute to improved survival in these poor-risk patients.
